
REPAIR-MDS Newsletter May 2022, Issue 03

Clinical Trials Day

REPAIR-MDS team celebrated Clinical Trials Day on 20th May by attending Warwick Clinical Trials Unit Poster Showcase event.



May Achievements

Kings College London Hospital has registered their 1st patient! We now have 4 participants registered!

Castle Hill Hospital is open to recruitment as of this month! Welcome onboard!

A big thank you to **Russell's Hall Hospital** for the 100% CRF completion rate. Keep up the good work!

REPAIRMDS

REPAIR-MDS Trials Team: 02476 575 675 | E-mail: repairMDS@warwick.ac.uk | Twitter: REPAIR-MDS_TRIAL (@REPAIR_MDS) / Twitter | Website: REPAIR MDS (warwick.ac.uk)

Screening logs

Screening data is really important for us to check our inclusion and exclusion criteria is correct and help us identify any barriers to recruitment as soon as possible!

Please include **all MDS patients** screened in your monthly screening log – including those patients:

- deemed ineligible at pre-screening
- have been informally reviewed
- attended your MDS clinic
- patients you have approached and are still considering the trial – you can update us when they have made their decision

Screening numbers should be sequential and carry over from month to month – this helps us track patients progress through the screening process

Don't hesitate to get in touch if you have any queries or require any support with screening - We are always happy to help! We have coded the most common reasons for patients to not be eligible or not wanting to enter the trial to streamline the process – You only need to note down the reason code listed on the last page of the screening log

Ster Screening Period (MMM/YYYY): Screening Period (MMM/YYY): Screening Period (MMM/YY): Screening Period (MMM/

Ethnicity codes	Reason codes if patient not eligible	Reason codes if patient not willing:
White	1. Eligible for ESA (erythropoietin)	32. No reason given
 A English, Welsh, Scottish, 	2. Diagnosis not definitively MDS	33. Wanted alternative treatment
Northern Irish or British	 IPSSR high, very high risk or AML 	34. Did not want to wait for
 Irish 	4. Women of childbearing potential	treatment allocation
C. Gypsy or Irish Traveller	 ECOG status >3 	35. Did not want to be part of a
 Any other White background 	6. Poor liver function defined as: ALT/AIRPhos > 3x ULN or Bilirubin > 3 x ULN (unless due to Gilberts Disease)	research study
Mixed or Multiple ethnic groups	7. Cockcroft Gault CrCl < 20mi/min	36. Unable to take part in trial
E. White and Black Caribbean	 Current systemic treatment for low risk MDS 	processes
 White and Black African 	9. History of Allogeneic Bone Marrow Transplant	
White and Asian	10. History of having received ESA and/or G-CSF in the past 16 weeks	
 Any other Mixed or Multiple 	11. Currently receiving statin medications for primary prophylaxis - patient/clinician elected to continue with statin medications	
ethnic background	12. Currently receiving statin medications for secondary prophylaxis	
Asian or Asian British	13. Currently receiving fibrate medications	
I. Indian	14. Prior investigational product for MDS	
L. Pakistani	15. Prior cytotoxic chemotherapy for AML/MDS	
K. Bangladeshi	16. Concurrent active malignancy requiring treatment	
L. Chinese	17. Currently receiving Vitamin K-Antagonist Anticoagulation (though patients receiving DDACs can be included)	
M. Any other Asian background	18. History of Venous Thrombo-Embolism (VTE)	
Black, African, Caribbean or Black	19. Cardiac Failure NYHA Class III or IV	
british	20. Known hypersensitivity to any of the investigational products	
African	21. Pregnancy or lactating	
0. Caribbean	22. The physician or patient consider VBaP or Danazol to be inappropriate for the patient.	
. Any other Black, African or	23. Known HIV	
Caribbean background	24. CK level > than 2.5 x ULN	
Other ethnic group	25. Presence of isolated del Sq	
2. Arab	26. Acute Porphyria	
R. Any other ethnic group	 Prognosis expected to be <12 months for any reason 	
	28. Contraindications to trial medication (e.g. Lapp lactase deficiency)	
	29. Previous randomisation in the REPAIR MDS trial.	
	30. Participation in a clinical trial of an investigational medicinal product in the last 90 days	
	31. Other, please specify	



Reminder - Bank Holiday Arrangements

A friendly reminder please do not plan to take or send any

Translational Research Samples to the Central Immunology Service during the Bank Holiday!

Emergency Randomisation Line & Central Trial Team

Unavailable from 17:00 Wednesday 1st June Will reopen 09:00 Monday 6th June

Central Immunology Service

Please do NOT take or send any samples during the Bank Holiday